13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839948
Total reported value
$4.2B
$4.2B
38 檔
6.0%
At the close of Q1 2025, TCG Crossover Management, LLC disclosed equity holdings valued at approximately $4.2B, spread across 38 reported holdings.
In Q1 2025, TCG Crossover Management, LLC adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 1 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including CGON, COGT, 260) accounted for 6.0% of total reported equity market value during Q1 2025.
Top Position Liquidated / Trimmed
KROS
前期市值: $8.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 12.26% | -0.84% | — | |
| 2 | COGT | Cogent Biosciences Inc | Stock-Other | 5.69% | -0.93% | — | |
| 3 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 5.67% | -4.87% | EXIT | |
| 4 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 5.35% | — | — | |
| 5 | OCUL | Ocular Therapeutix Inc | Stock-Other | 5.32% | -0.01% | — | |
| 6 | ABVX | Abivax Sa-adr | Stock-Other | 5.16% | -1.41% | — | |
| 7 | SVRA | Savara Inc | Stock-Other | 4.67% | -0.10% | — | |
| 8 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.78% | +0.07% | — | |
| 9 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.72% | -0.10% | — | |
| 10 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.68% | -1.07% | +45.70% | |
| 11 | XNCR | Xencor Inc | Stock-Other | 3.56% | +0.10% | — | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 3.15% | -0.09% | -4.46% | |
| 13 | TRML | Tourmaline Bio Inc | Stock-Other | 3.07% | — | — | |
| 14 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.96% | — | — | |
| 15 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 2.87% | +0.22% | +27.99% | |
| 16 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.68% | — | -50.00% | |
| 17 | EYPT | Eyepoint Inc | Stock-Other | 2.64% | — | — | |
| 18 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.51% | -0.19% | EXIT | |
| 19 | UPB | Upstream Bio Inc | Stock-Other | 2.34% | -0.05% | EXIT | |
| 20 | ✓ | Rapt Therapeutics Inc | Stock-Other | 2.18% | — | -0.34% | |
| 21 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 2.06% | -1.15% | EXIT | |
| 22 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.01% | — | — | |
| 23 | TNGX | Tango Therapeutics Inc | Stock-Other | 2.01% | +0.52% | — | |
| 24 | CMPS | Compass Pathways PLC | Stock-Other | 1.51% | — | — | |
| 25 | KURA | Kura Oncology Inc | Stock-Other | 1.28% | — | — | |
| 26 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.19% | — | — | |
| 27 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.17% | +0.34% | — | |
| 28 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 1.07% | — | — | |
| 29 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.91% | -0.04% | EXIT | |
| 30 | ✓ | Stock-Other | 0.77% | — | — | ||
| 31 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.72% | -0.64% | — | |
| 32 | MBX | Mbx Biosciences Inc | Stock-Other | 0.65% | +0.30% | — | |
| 33 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.53% | +1.02% | — | |
| 34 | KOD | Kodiak Sciences Inc | Stock-Other | 0.44% | -0.23% | — | |
| 35 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.37% | — | — | |
| 36 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.05% | — | — | |
| 37 | CABA | Cabaletta Bio Inc | Stock-Other | 0.02% | — | — | |
| 38 | KROS | Keros Therapeutics Inc | Stock-Other | — | — | -100.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MLYS | Mineralys Therapeutics Inc | +2.4% | — | Unchanged |
| 2 | CGON | Cg Oncology Inc | +2% | — | Unchanged |
| 3 | AMLX | Amylyx Pharmaceuticals Inc | +1.2% | +27.99% | Add |
| 4 | TYRA | Tyra Biosciences Inc | +1% | +45.70% | Add |
| 5 | SVRA | Savara Inc | +1% | — | Unchanged |
| 6 | 260 | Centessa Pharmaceuticals-adr | +0.9% | — | Unchanged |
| 7 | OCUL | Ocular Therapeutix Inc | +0.9% | — | Unchanged |
| 8 | ABVX | Abivax Sa-adr | +0.8% | — | Unchanged |
| 9 | DNTH | Dianthus Therapeutics Inc | +0.5% | — | Unchanged |
| 10 | CDTX | Cidara Therapeutics Inc | +0.4% | — | Unchanged |
| 11 | COGT | Cogent Biosciences Inc | +0.4% | — | Unchanged |
| 12 | SLNOEUR | Soleno Therapeutics Inc | +0.3% | -50.00% | Trim |
| 13 | ✓ | Rapt Therapeutics Inc | +0.3% | -0.34% | Trim |
| 14 | AVU0 | Adverum Biotechnologies Inc | +0.3% | — | Unchanged |
| 15 | ✓ | +0.2% | — | Unchanged | |
| 16 | AVTX | Avalo Therapeutics Inc | +0.2% | — | Unchanged |
| 17 | TRML | Tourmaline Bio Inc | +0.1% | — | Unchanged |
| 18 | VTGN | Vistagen Therapeutics Inc | +0.1% | — | Unchanged |
| 19 | IRON | Disc Medicine Inc | +0.1% | -4.46% | Trim |
| 20 | CMPS | Compass Pathways PLC | +0.1% | — | Unchanged |
| 21 | KURA | Kura Oncology Inc | +0.1% | — | Unchanged |
| 22 | EYPT | Eyepoint Inc | 0% | — | Unchanged |
| 23 | NKTREUR | Nektar Therapeutics | 0% | — | Unchanged |
| 24 | CABA | Cabaletta Bio Inc | — | — | Unchanged |
| 25 | VTYXUSD | Ventyx Biosciences Inc | 0% | — | Unchanged |
| 26 | TRDA | Entrada Therapeutics Inc | -0.3% | — | Unchanged |
| 27 | GPCR | Structure Therapeutics Inc | -0.3% | — | Unchanged |
| 28 | FULC | Fulcrum Therapeutics Inc | -0.4% | — | Unchanged |
| 29 | CATBUSD | Astria Therapeutics Inc | -0.4% | — | Unchanged |
| 30 | MBX | Mbx Biosciences Inc | -0.5% | — | Unchanged |
| 31 | KOD | Kodiak Sciences Inc | -0.7% | — | Unchanged |
| 32 | KROS | Keros Therapeutics Inc | -0.9% | EXIT | Sold out |
| 33 | SLN | Silence Therapeutics Plc-adr | -0.9% | — | Unchanged |
| 34 | TNGX | Tango Therapeutics Inc | -1.2% | — | Unchanged |
| 35 | ✓ | Third Harmonic Bio Inc | -1.3% | — | Unchanged |
| 36 | XNCR | Xencor Inc | -2% | — | Unchanged |
| 37 | UPB | Upstream Bio Inc | -2% | — | Unchanged |
| 38 | DYN | Dyne Therapeutics Inc | -2.3% | — | Unchanged |
According to official SEC Form 13F filings, TCG Crossover Management, LLC reported a total U.S. public equity portfolio value of $4.2B across 38 disclosed positions in Q1 2025.
During Q1 2025, TCG Crossover Management, LLC's top holdings by market value included CGON (12.3%)、COGT (5.7%)、260 (5.7%). The largest single position, CGON, represented 12.3% of total portfolio value.
In Q1 2025, TCG Crossover Management, LLC made 6 total portfolio adjustments, initiating 0 new buys, adding to 2 positions, trimming 3 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.